Since our data indicated that hEpAb2-6 could prevent EpICD-mediated upregulation of Wnt receptor (FZD6 and LRP5/6) transcription and related phenomena, we next sought to test whether hEpAb2-6 conferred therapeutic benefit in laboratory models of CRC. This evidence concerns the gene FZD6 and colorectal carcinoma.